Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.
While the majority of current diabetes treatments focus on reducing blood glucose levels, hypoglycemia represents a significant risk associated with insulin treatment. Glucagon plays a major regulatory role in controlling hypoglycemia in vivo, but its short half-life and hyperglycemic effects preven...
Main Authors: | Nathan C Geething, Wayne To, Benjamin J Spink, Michael D Scholle, Chia-wei Wang, Yong Yin, Yi Yao, Volker Schellenberger, Jeffrey L Cleland, Willem P C Stemmer, Joshua Silverman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-04-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2854692?pdf=render |
Similar Items
-
GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.
by: Susan E Alters, et al.
Published: (2012-01-01) -
GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One. 2012; 7(11): e50630.
by: Susan E Alters, et al.
Published: (2013-01-01) -
XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic.
by: Akvile Haeckel, et al.
Published: (2016-01-01) -
AAV GCG-EGFP, a new tool to identify glucagon-secreting α-cells
by: Eva Tudurí, et al.
Published: (2019-07-01) -
Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia
by: Antonio E. Pontiroli, et al.
Published: (2019-07-01)